| This week's sponsor is Premier Research. | | | Beyond Intensity: The Full Impact of Fibromyalgia Pain
Patient-reported outcomes drive fibromyalgia drug research, and pain intensity is one measure of many. Download our white paper to gauge the many related symptoms. Premier Research. It's what we do. Best. |
Today's Rundown Bristol-Myers chops clinical staff as site closure enters endgame Mesoblast prepares first filings for GVHD drug after phase 3 win GeneTx Biotherapeutics launches to take on Angelman syndrome [Sponsored] Optimizing Humanized Model Selection for Enhanced Preclinical Immunotherapy Assessment Merck's ERK inhibitor shows promise in combination against resistant cancers Teva shutters New York, D.C. offices and dismisses lobbyists as part of U.S. consolidation drive EuroBiotech Report—GW’s trial fail, Arix-Ipsen, Medigene T-cell trial and Santhera in DMD FiercePharmaAsia—More Takeda deals, China’s pharma supply issues, Merck KGaA expansion Chutes & Ladders—Pfizer’s early clinical head lands as Magenta CMO Featured Story | | | Friday, February 23, 2018 Bristol-Myers Squibb is set to lay off 107 staffers at its Wallingford, Connecticut, site as its planned closure of the facility gathers pace. Having earmarked the site for staff reductions in 2015, Bristol-Myers is now doling out pink slips at an accelerating rate as it gets closer to shuttering by the end of the year. |
|
|
| This week's sponsor is NYCEDC. | | | |
Top Stories Friday, February 23, 2018 A late-stage study of Mesoblast’s off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD) has hit its main goal, setting up an imminent U.S. filing. Friday, February 23, 2018 GeneTx will develop an antisense drug for Angelman syndrome, a genetic disorder that affects the nervous system. Tuesday, February 20, 2018 Tumor-bearing humanized models are vital preclinical platforms for assessing human-specific immunotherapies. Review immediately transferable humanized model strategies for accelerating immunotherapy drug discovery programs. Thursday, February 22, 2018 One-fifth of patients in a phase 1 study responded to Merck's ERK inhibitor, a comparable response rate to other cancer drugs, such as MEK inhibitors. The results suggest the drug could be used in tandem with another to fight cancers with a specific mutation. Friday, February 23, 2018 Teva is working to consolidate seven U.S. offices under one roof, and that means saying bye-bye to its New York and Washington, D.C., locations. Thursday, February 22, 2018 In this week's EuroBiotech Report, GW’s proof-of-concept trial faIls, Arix hooks up with Ipsen, Medigene trial gets green light and more. Friday, February 23, 2018 Takeda made R&D deals in neurological disorders and with academic institutions, China's crackdown on pollution has caused some supply issues for the pharma industry, Merck KGaA plans further manufacturing expansions in Asia and more. Friday, February 23, 2018 Fierce 15 winner Magenta Therapeutics recruits Pfizer executive John Davis, M.D., as its CMO; former Teva executive Siggi Olafsson re-emerges at Hikma Pharmaceuticals; plus more hirings, firings and retirings throughout the industry. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Presented by: Box and USDM Life Sciences Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process. Sponsored by: RBC Wealth Management Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA PEGS: The Essential Protein Engineering Summit April 30-May 4 | Boston, MA Partnering for Growth 2018 March 20th | 7:30 am-6 pm
March 21st | 7:30 am-1:15 pm Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 